At the time of writing, Celldex Therapeutics Inc [CLDX] stock is trading at $27.13, up 1.34%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CLDX shares have gain 2.84% over the last week, with a monthly amount glided 10.96%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Celldex Therapeutics Inc [NASDAQ: CLDX] stock has seen the most recent analyst activity on October 13, 2025, when Barclays initiated its Underweight rating and assigned the stock a price target of $25. Previously, Canaccord Genuity started tracking the stock with Buy rating on April 28, 2025, and set its price target to $64. On March 20, 2025, Morgan Stanley initiated with a Overweight rating and assigned a price target of $46 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $44 on February 13, 2025. Citigroup initiated its recommendation with a Buy and recommended $70 as its price target on October 07, 2024. Goldman started tracking with a Neutral rating for this stock on September 30, 2024, and assigned it a price target of $45. In a note dated September 27, 2024, Wolfe Research downgraded an Peer Perform rating on this stock.
For the past year, the stock price of Celldex Therapeutics Inc fluctuated between $14.40 and $31.66. Currently, Wall Street analysts expect the stock to reach $25 within the next 12 months. Celldex Therapeutics Inc [NASDAQ: CLDX] shares were valued at $27.13 at the most recent close of the market. An investor can expect a potential drop of -7.85% based on the average CLDX price forecast.
Analyzing the CLDX fundamentals
According to Celldex Therapeutics Inc [NASDAQ:CLDX], the company’s sales were 5.79M for trailing twelve months, which represents an -70.78% plunge. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -40.54%, Pretax Profit Margin comes in at -34.47%, and Net Profit Margin reading is -34.47%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.28 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Celldex Therapeutics Inc [NASDAQ:CLDX] has a current ratio of 19.67. Also, the Quick Ratio is 19.67, while the Cash Ratio stands at 0.7. Considering the valuation of this stock, the price to sales ratio is 311.16, the price to book ratio is 2.75.
Transactions by insiders
Recent insider trading involved Jimenez Freddy A., SVP & GENERAL COUNSEL, that happened on Aug 13 ’25 when 771.0 shares were sold. PRESIDENT & CEO, Marucci Anthony S completed a deal on Nov 11 ’24 to buy 11500.0 shares.
